Yahoo Finance

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative ...
Pharmabiz

Lipella Pharma receives US FDA nod for expanded access programme for LP-310, an oral rinse formulation to treat oral lichen planus

Lipella Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing innovative therapies by reformulating active agents in existing generic drugs, announced that the US Food and ...
Yahoo Finance

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical ...
Pharm Exec

FDA Clears Investigational New Drug Application for Lipella’s Oral Lichen Planus Treatment

LP-310 designated as an oral formulation of company’s LP-10 asset. Lipella Pharmaceuticals announced that the FDA has approved an investigational new drug (IND) application for a multi-center, Phase ...
Barron's

Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous ...